Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study
Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study Herantis Pharma PlcCompany release 19 October 2017 at 4:00 pm Not for publication or distribution, directly or indirectly, in or into Australia, South Africa, Hong Kong, Japan, Canada or the United States of America or in any other jurisdiction in which publishing or distributing would be prohibited by applicable law Herantis Pharma Plc ("Herantis" or the "Company") is planning a directed share issue to